BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22027536)

  • 1. Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity.
    Aparicio LM; Pulido EG; Gallego GA
    Anticancer Drugs; 2012 Jan; 23(1):1-11. PubMed ID: 22027536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules.
    Ngan VK; Bellman K; Panda D; Hill BT; Jordan MA; Wilson L
    Cancer Res; 2000 Sep; 60(18):5045-51. PubMed ID: 11016627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vinflunine, a new vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells.
    Jean-Decoster C; Brichese L; Barret JM; Tollon Y; Kruczynski A; Hill BT; Wright M
    Anticancer Drugs; 1999 Jul; 10(6):537-43. PubMed ID: 10885901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.
    Jordan MA; Horwitz SB; Lobert S; Correia JJ
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S6-S12. PubMed ID: 18538179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties.
    Kruczynski A; Hill BT
    Crit Rev Oncol Hematol; 2001 Nov; 40(2):159-73. PubMed ID: 11682323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential mechanisms of resistance to microtubule inhibitors.
    Kavallaris M; Annereau JP; Barret JM
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells.
    Pourroy B; Honoré S; Pasquier E; Bourgarel-Rey V; Kruczynski A; Briand C; Braguer D
    Cancer Res; 2006 Mar; 66(6):3256-63. PubMed ID: 16540678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tubulin and microtubules as targets for anticancer drugs.
    Hadfield JA; Ducki S; Hirst N; McGown AT
    Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, metabolites, and preclinical safety of vinflunine.
    Lobert S; Puozzo C
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S28-33. PubMed ID: 18538176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP.
    Makarov AA; Tsvetkov PO; Villard C; Esquieu D; Pourroy B; Fahy J; Braguer D; Peyrot V; Lafitte D
    Biochemistry; 2007 Dec; 46(51):14899-906. PubMed ID: 18052208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of vinflunine: effector pathways and potential for synergies.
    Braguer D; Barret JM; McDaid H; Kruczynski A
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S13-21. PubMed ID: 18538174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine.
    Ngan VK; Bellman K; Hill BT; Wilson L; Jordan MA
    Mol Pharmacol; 2001 Jul; 60(1):225-32. PubMed ID: 11408618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules in vitro.
    Himes RH; Kersey RN; Heller-Bettinger I; Samson FE
    Cancer Res; 1976 Oct; 36(10):3798-802. PubMed ID: 954003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development.
    Kruczynski A; Poli M; Dossi R; Chazottes E; Berrichon G; Ricome C; Giavazzi R; Hill BT; Taraboletti G
    Eur J Cancer; 2006 Nov; 42(16):2821-32. PubMed ID: 16973349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of action of antitumor drugs that interact with microtubules and tubulin.
    Jordan MA
    Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):1-17. PubMed ID: 12678749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vinflunine, a second generation novel Vinca Alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers.
    Hill BT
    Curr Pharm Des; 2001 Sep; 7(13):1199-212. PubMed ID: 11472262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.
    Kruczynski A; Barret JM; Etiévant C; Colpaert F; Fahy J; Hill BT
    Biochem Pharmacol; 1998 Mar; 55(5):635-48. PubMed ID: 9515574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity.
    Lobert S; Ingram JW; Hill BT; Correia JJ
    Mol Pharmacol; 1998 May; 53(5):908-15. PubMed ID: 9584218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class.
    Owellen RJ; Hartke CA; Dickerson RM; Hains FO
    Cancer Res; 1976 Apr; 36(4):1499-502. PubMed ID: 1260766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microtubules: a dynamic target in cancer therapy.
    Pasquier E; Kavallaris M
    IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.